标题
Biologics for severe asthma and beyond
作者
关键词
-
出版物
PHARMACOLOGY & THERAPEUTICS
Volume -, Issue -, Pages 108551
出版商
Elsevier BV
发表日期
2023-10-30
DOI
10.1016/j.pharmthera.2023.108551
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Asthma management and control in children, adolescents, and adults in 25 countries: a Global Asthma Network Phase I cross-sectional study
- (2023) Luis García-Marcos et al. Lancet Global Health
- A2BCD: a concise guide for asthma management
- (2023) Marek Lommatzsch et al. Lancet Respiratory Medicine
- Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study
- (2023) Andrew Menzies-Gow et al. Lancet Respiratory Medicine
- Real-world efficacy of anti-IL-5 treatment in patients with allergic bronchopulmonary aspergillosis
- (2023) Katsuyoshi Tomomatsu et al. Scientific Reports
- Response to biologics and clinical remission in the adult GAN severe asthma registry cohort
- (2023) Katrin Milger et al. Journal of Allergy and Clinical Immunology-In Practice
- Kriterien zur Evaluation des Ansprechens auf Biologika bei schwerem Asthma – der Biologics Asthma Response Score (BARS)
- (2023) Katrin Milger et al. PNEUMOLOGIE
- Biologics (mepolizumab and omalizumab) induced remission in severe asthma patients
- (2023) Dennis Thomas et al. ALLERGY
- Biologic Therapies for Severe Asthma
- (2022) Guy G. Brusselle et al. NEW ENGLAND JOURNAL OF MEDICINE
- Real World Biologic Use and Switch Patterns in Severe Asthma: Data from the International Severe Asthma Registry and the US CHRONICLE Study
- (2022) Andrew N Menzies-Gow et al. Journal of Asthma and Allergy
- Asthma Control in Patients with Severe Eosinophilic Asthma Treated with Reslizumab: Spanish Real-Life Data
- (2022) Luis A Pérez de Llano et al. Journal of Asthma and Allergy
- Safety of combining biologics in severe asthma: asthma‐related and unrelated combinations
- (2022) Marek Lommatzsch et al. ALLERGY
- Disease-modifying anti-asthmatic drugs
- (2022) Marek Lommatzsch et al. LANCET
- Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma (SOURCE): a randomised, placebo-controlled, phase 3 study
- (2022) Michael E Wechsler et al. Lancet Respiratory Medicine
- Real-World Effectiveness of Reslizumab in Patients With Severe Eosinophilic Asthma – First Initiators and Switchers
- (2022) Simone Hashimoto et al. Journal of Allergy and Clinical Immunology-In Practice
- Real-World Effectiveness of Dupilumab for Patients with Severe Asthma: A Retrospective Study
- (2022) Takanori Numata et al. Journal of Asthma and Allergy
- Overall response to anti-IL5/anti-IL5Rα treatment in severe asthma does not depend on initial bronchodilator responsiveness
- (2022) Carlo Mümmler et al. Journal of Allergy and Clinical Immunology-In Practice
- REALITI-A Study: Real-World Oral Corticosteroid-Sparing Effect of Mepolizumab in Severe Asthma
- (2022) Charles Pilette et al. Journal of Allergy and Clinical Immunology-In Practice
- Dupilumab in Adults and Adolescents with Eosinophilic Esophagitis
- (2022) Evan S. Dellon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rapid effect of benralizumab in exacerbation of severe eosinophilic asthma associated with eosinophilic granulomatosis with polyangiitis
- (2021) Carlos Martínez-Rivera et al. BMC Pulmonary Medicine
- The relationship between FeNO and effectiveness of mepolizumab and benralizumab in severe eosinophilic asthma
- (2021) A.P. Hearn et al. Journal of Allergy and Clinical Immunology-In Practice
- Complications of switching from anti-IL-5 or anti-IL-5R to dupilumab in corticosteroid-dependent severe asthma
- (2021) Katrien Eger et al. Journal of Allergy and Clinical Immunology-In Practice
- Real-world efficacy and safety of dupilumab use in the treatment of asthma
- (2021) Somaira Nowsheen et al. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY
- Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: a randomized clinical trial
- (2021) Steven G. Kelsen et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma
- (2021) Andrew Menzies-Gow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2021) Joseph K Han et al. Lancet Respiratory Medicine
- Eosinophilic pleural effusion and stroke with cutaneous vasculitis: Two cases of dupilumab‐induced hypereosinophilia
- (2021) Marek Lommatzsch et al. ALLERGY
- Impact of baseline patient characteristics on dupilumab efficacy in type 2 asthma
- (2021) William W. Busse et al. EUROPEAN RESPIRATORY JOURNAL
- Hypereosinophilia with systemic manifestations under dupilumab and possibility of dual benralizumab and dupilumab therapy in patients with asthma and CRSwNP
- (2021) Ignaz Briegel et al. Journal of Allergy and Clinical Immunology-In Practice
- Real-World Multicenter Experience with Mepolizumab and Benralizumab in the Treatment of Uncontrolled Severe Eosinophilic Asthma Over 12 Months
- (2021) Moritz Z Kayser et al. Journal of Asthma and Allergy
- Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma
- (2021) Michael E. Wechsler et al. NEW ENGLAND JOURNAL OF MEDICINE
- Risankizumab in Severe Asthma — A Phase 2a, Placebo-Controlled Trial
- (2021) Christopher E. Brightling et al. NEW ENGLAND JOURNAL OF MEDICINE
- Real-world study in severe eosinophilic asthma patients refractory to anti-IL5 biological agents treated with benralizumab in Spain (ORBE study)
- (2021) Eva Martínez-Moragón et al. BMC Pulmonary Medicine
- Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study
- (2021) Andrew Menzies-Gow et al. Lancet Respiratory Medicine
- Effective Management of Severe Asthma with Biologic Medications in Adult Patients: A Literature Review and International Expert Opinion
- (2021) Roland Buhl et al. Journal of Allergy and Clinical Immunology-In Practice
- Reduced exacerbation frequency and prednisone dose in patients with ABPA and asthma treated with dupilumab
- (2021) Tjeerd Veer et al. Clinical and Translational Allergy
- Successful treatment of refractory status asthmaticus with omalizumab: a case report
- (2021) Jan Benes et al. Allergy Asthma and Clinical Immunology
- Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: A randomized, placebo-controlled trial
- (2021) Claus Bachert et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Mepolizumab effectiveness and identification of super-responders in severe asthma
- (2020) Erin S. Harvey et al. EUROPEAN RESPIRATORY JOURNAL
- Mepolizumab add-on therapy in a real world cohort of patients with severe eosinophilic asthma: response rate, effectiveness, and safety
- (2020) Jermo Johannes van Toor et al. JOURNAL OF ASTHMA
- Real-World Effectiveness and the Characteristics of a “Super-Responder” to Mepolizumab in Severe Eosinophilic Asthma
- (2020) Joanne E. Kavanagh et al. CHEST
- Effectiveness and safety of dupilumab for the treatment of severe asthma in a real‐life French multi‐centre adult cohort
- (2020) Clairelyne Dupin et al. CLINICAL AND EXPERIMENTAL ALLERGY
- Psoriasis bei Dupilumab-behandeltem atopischem Ekzem
- (2020) S. Senner et al. HAUTARZT
- Mepolizumab for allergic bronchopulmonary aspergillosis: Report of 20 cases from the Belgian Severe Asthma Registry and review of the literature
- (2020) Florence Schleich et al. Journal of Allergy and Clinical Immunology-In Practice
- Real-world mepolizumab in the prospective severe asthma REALITI-A study – initial analysis
- (2020) Tim Harrison et al. EUROPEAN RESPIRATORY JOURNAL
- Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials
- (2020) Philippe Gevaert et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Real-life experience with benralizumab during 6 months
- (2020) A. Padilla-Galo et al. BMC Pulmonary Medicine
- Benralizumab as a glucocorticoid-sparing treatment option for severe asthma in eosinophilic granulomatosis with polyangiitis
- (2020) Roberto Padoan et al. Journal of Allergy and Clinical Immunology-In Practice
- Differential response to biologics in a patient with severe asthma and ABPA: a role for dupilumab?
- (2020) Carlo Mümmler et al. Allergy Asthma and Clinical Immunology
- Real World Effectiveness of Benralizumab in Severe Eosinophilic Asthma
- (2020) Joanne E. Kavanagh et al. CHEST
- Efficacy and safety of mepolizumab in hypereosinophilic syndrome: A phase III, randomized, placebo-controlled trial
- (2020) Florence Roufosse et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Significant improvement in lung function and asthma control after benralizumab treatment for severe refractory eosinophilic asthma
- (2020) Francesco Menzella et al. PULMONARY PHARMACOLOGY & THERAPEUTICS
- Benralizumab as a steroid-sparing treatment option in eosinophilic granulomatosis with polyangiitis
- (2020) Vamsi P. Guntur et al. Journal of Allergy and Clinical Immunology-In Practice
- Dupilumab Improves Asthma Control and Lung Function in Patients with Insufficient Outcome During Previous Antibody Therapy
- (2020) Carlo Mümmler et al. Journal of Allergy and Clinical Immunology-In Practice
- Benralizumab after sub‐optimal response to mepolizumab in severe eosinophilic asthma
- (2020) Joanne E. Kavanagh et al. ALLERGY
- Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial
- (2020) Tim W Harrison et al. Lancet Respiratory Medicine
- Higher Blood Eosinophil Levels after Omalizumab Treatment Are Associated with Poorer Asthma Outcomes.
- (2019) Bruno Sposato et al. Journal of Allergy and Clinical Immunology-In Practice
- Case series of allergic bronchopulmonary aspergillosis treated successfully and safely with long-term mepolizumab
- (2019) Seiko Soeda et al. ALLERGOLOGY INTERNATIONAL
- The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma
- (2019) Kenneth R. Chapman et al. ALLERGY
- Conjunctivitis in dupilumab clinical trials
- (2019) B. Akinlade et al. BRITISH JOURNAL OF DERMATOLOGY
- Epithelial cell–derived cytokines: more than just signaling the alarm
- (2019) Florence Roan et al. JOURNAL OF CLINICAL INVESTIGATION
- Benralizumab for PDGFRA-Negative Hypereosinophilic Syndrome
- (2019) Fei Li Kuang et al. NEW ENGLAND JOURNAL OF MEDICINE
- Decrease in MPO-ANCA after administration of benralizumab in eosinophilic granulomatosis with polyangiitis
- (2019) Kenchi Takenaka et al. ALLERGOLOGY INTERNATIONAL
- Combination biologic therapy for severe persistent asthma
- (2019) Gilbert Ortega et al. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY
- A case of chronic eosinophilic pneumonia in a patient treated with dupilumab
- (2019) Francesco Menzella et al. Therapeutics and Clinical Risk Management
- Management of Severe Asthma: a European Respiratory Society/American Thoracic Society Guideline
- (2019) Fernando Holguin et al. EUROPEAN RESPIRATORY JOURNAL
- Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials
- (2019) Claus Bachert et al. LANCET
- Mepolizumab and reslizumab, two different options for severe asthma patients with prior failure to omalizumab
- (2019) Luis A. Pérez de Llano et al. ALLERGY
- Real-life rapidity of benralizumab effects in patients with severe allergic eosinophilic asthma: Assessment of blood eosinophils, symptom control, lung function and oral corticosteroid intake after the first drug dose
- (2019) Corrado Pelaia et al. PULMONARY PHARMACOLOGY & THERAPEUTICS
- Dual blockade of IL‐4 and IL‐13 with dupilumab, an IL‐4Rα antibody, is required to broadly inhibit type 2 inflammation
- (2019) Audrey Le Floc’h et al. ALLERGY
- An expert consensus framework for asthma remission as a treatment goal
- (2019) Andrew Menzies-Gow et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Dupilumab treatment for allergic bronchopulmonary aspergillosis: A case series
- (2019) Richard Paul Ramonell et al. Journal of Allergy and Clinical Immunology-In Practice
- Weight-adjusted Intravenous Reslizumab in Severe Asthma with Inadequate Response to Fixed-Dose Subcutaneous Mepolizumab
- (2018) Manali Mukherjee et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma
- (2018) Bradley E. Chipps et al. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY
- Omalizumab effectiveness in patients with severe allergic asthma according to blood eosinophil count: the STELLAIR study
- (2018) Marc Humbert et al. EUROPEAN RESPIRATORY JOURNAL
- Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma
- (2018) Klaus F. Rabe et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma
- (2018) Mario Castro et al. NEW ENGLAND JOURNAL OF MEDICINE
- A case of allergic bronchopulmonary aspergillosis successfully treated with mepolizumab
- (2018) Takeshi Terashima et al. BMC Pulmonary Medicine
- Anti-IL-5 therapy in patients with severe eosinophilic asthma – clinical efficacy and possible criteria for treatment response
- (2018) Nora Drick et al. BMC Pulmonary Medicine
- Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies
- (2018) J Mark FitzGerald et al. Lancet Respiratory Medicine
- Omalizumab Effectiveness by Biomarker Status in Patients with Asthma: Evidence From PROSPERO, A Prospective Real-World Study
- (2018) Thomas B. Casale et al. Journal of Allergy and Clinical Immunology-In Practice
- Baseline Patient Factor Impact on the Clinical Efficacy of Benralizumab for Severe Asthma
- (2018) Eugene R. Bleecker et al. EUROPEAN RESPIRATORY JOURNAL
- Omalizumab Rescue Therapy for Refractory Status Asthmaticus
- (2018) Katrin Milger et al. ANNALS OF INTERNAL MEDICINE
- Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial
- (2018) William W Busse et al. Lancet Respiratory Medicine
- Allergic bronchopulmonary aspergillosis successfully treated with benralizumab
- (2018) Seiko Soeda et al. Journal of Allergy and Clinical Immunology-In Practice
- Omalizumab in the treatment of eosinophilic granulomatosis with polyangiitis (EGPA): single-center experience in 18 cases
- (2018) Zeynep Celebi Sozener et al. World Allergy Organization Journal
- Biologic treatment eligibility for real-world patients with severe asthma: The IDEAL study
- (2017) Frank C. Albers et al. JOURNAL OF ASTHMA
- Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis
- (2017) Michael E. Wechsler et al. NEW ENGLAND JOURNAL OF MEDICINE
- Oral Glucocorticoid–Sparing Effect of Benralizumab in Severe Asthma
- (2017) Parameswaran Nair et al. NEW ENGLAND JOURNAL OF MEDICINE
- Reslizumab in patients with inadequately controlled late-onset asthma and elevated blood eosinophils
- (2017) Guy Brusselle et al. PULMONARY PHARMACOLOGY & THERAPEUTICS
- Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial
- (2017) Geoffrey L Chupp et al. Lancet Respiratory Medicine
- “Real-life” Effectiveness Studies of Omalizumab in Adult Patients with Severe Allergic Asthma: Meta-analysis
- (2017) Abdulaziz Alhossan et al. Journal of Allergy and Clinical Immunology-In Practice
- Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment
- (2016) A. Magnan et al. ALLERGY
- Phase 3 Study of Reslizumab in Patients With Poorly Controlled Asthma
- (2016) Jonathan Corren et al. CHEST
- Reslizumab for Inadequately Controlled Asthma With Elevated Blood Eosinophil Levels
- (2016) Leif Bjermer et al. CHEST
- Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial
- (2016) Eugene R Bleecker et al. LANCET
- Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial
- (2016) J Mark FitzGerald et al. LANCET
- Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
- (2016) Eric L. Simpson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anti-IgE Monoclonal Antibody (Omalizumab) in Refractory and Relapsing Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss): Data on Seventeen Patients
- (2016) Marie Jachiet et al. Arthritis & Rheumatology
- Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies
- (2016) Hector G Ortega et al. Lancet Respiratory Medicine
- Omalizumab in the treatment of allergic bronchopulmonary aspergillosis: One center's experience with 14 cases
- (2015) Ömür Aydın et al. ALLERGY AND ASTHMA PROCEEDINGS
- The Xolair Pregnancy Registry (EXPECT): The safety of omalizumab use during pregnancy
- (2015) Jennifer Namazy et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Omalizumab in patients with eosinophilic granulomatosis with polyangiitis: a 36-month follow-up study
- (2015) Aikaterini Detoraki et al. JOURNAL OF ASTHMA
- Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials
- (2015) Mario Castro et al. Lancet Respiratory Medicine
- Clinical Efficacy and Immunologic Effects of Omalizumab in Allergic Bronchopulmonary Aspergillosis
- (2015) Astrid L. Voskamp et al. Journal of Allergy and Clinical Immunology-In Practice
- The role of mepolizumab in atopic and nonatopic severe asthma with persistent eosinophilia
- (2014) H. Ortega et al. EUROPEAN RESPIRATORY JOURNAL
- Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma
- (2014) Elisabeth H. Bel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma
- (2014) Hector G. Ortega et al. NEW ENGLAND JOURNAL OF MEDICINE
- Heterogeneity of phenotypes in severe asthmatics. The Belgian Severe Asthma Registry (BSAR)
- (2014) F. Schleich et al. RESPIRATORY MEDICINE
- Exploring the Effects of Omalizumab in Allergic Asthma
- (2013) Nicola A. Hanania et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Omalizumab in Severe Allergic Asthma Inadequately Controlled With Standard Therapy
- (2013) Nicola A. Hanania et al. ANNALS OF INTERNAL MEDICINE
- International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma
- (2013) K. F. Chung et al. EUROPEAN RESPIRATORY JOURNAL
- High eosinophil count: A potential biomarker for assessing successful omalizumab treatment effects
- (2013) William Busse et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Measures of gene expression in sputum cells can identify TH2-high and TH2-low subtypes of asthma
- (2013) Michael C. Peters et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Omalizumab for the Treatment of Chronic Idiopathic or Spontaneous Urticaria
- (2013) Marcus Maurer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Global asthma prevalence in adults: findings from the cross-sectional world health survey
- (2012) Teresa To et al. BMC PUBLIC HEALTH
- Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial
- (2012) Ian D Pavord et al. LANCET
- Allergic bronchopulmonary aspergillosis and omalizumab
- (2011) I. Tillie-Leblond et al. ALLERGY
- Effects of omalizumab in Aspergillus-associated airway disease
- (2011) L. A. Perez-de-Llano et al. THORAX
- Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome
- (2010) Sophia Kim et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- MEDI-563, a humanized anti–IL-5 receptor α mAb with enhanced antibody-dependent cell-mediated cytotoxicity function
- (2010) Roland Kolbeck et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Churg-Strauss Syndrome in Patients Treated With Omalizumab
- (2009) Michael E. Wechsler et al. CHEST
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation